Kymera Therapeutics logo
Kymera Therapeutics
KYMR | NASDAQ
Chart Builder DCF Calculator
$125.85
-$1.72 (-1.35%)
At close: Nov 16, 2026, 4:00 PM ET
$123.50
-$2.35 (-1.87%)
After-hours: Nov 16, 2026, 7:59 PM ET

Kymera Therapeutics Company Profile

Company profile explained

Company Profile

Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins. The company's pipeline features several programs, including the IRAK4 program, currently in Phase I clinical trials, which targets various immunology-inflammation disorders such as hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, generalized pustular psoriasis, and rheumatoid arthritis. Additionally, Kymera is advancing its IRAKIMiD program, designed to address MYD88-mutated diffuse large B cell lymphoma. Other key programs include the STAT3 program, focused on hematological malignancies, solid tumors, autoimmune diseases, and fibrosis, as well as the MDM2 program, which is also aimed at hematological malignancies and solid tumors. The company was founded in 2015 and maintains its headquarters in Watertown, Massachusetts.

Key Executives

Name Position
Nello Mainolfi Co-Founder, President, Chief Executive Officer & Director
Brian R. Adams Chief Legal Officer & Corporate Secretary
Bruce N. Jacobs Chief Financial Officer
Brian Albarran SVP of Corporate Strategy
Jared A. Gollob Advisor
Jeremy G. Chadwick Advisor
Juliet Williams Head of Research
Justine E. Koenigsberg Vice President of Investor Relations
Neil Graham MBBS Chief Development Officer
Noah Goodman Chief Business Officer

Latest SEC Filings

Date Type Title
Oct 29, 2026 10-Q Quarterly Report
Oct 29, 2026 8-K Current Report
Oct 27, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Oct 01, 2026 4 Filing
Sep 08, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Sep 04, 2026 4 Filing
Aug 14, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Aug 13, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Aug 05, 2026 10-Q Quarterly Report
Aug 05, 2026 8-K Current Report
View All SEC Filings ➞
Kymera Therapeutics
Kymera Therapeutics logo
Country United States
IPO Date Aug 21, 2020
Industry Biotechnology
Sector Healthcare
Employees 273
CEO Nello Mainolfi

Contact Details

500 North Beacon Street Watertown, Massachusetts 02472 United States

Stock Details

Ticker Symbol KYMR
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001815442
CUSIP Number 501575104
ISIN Number US5015751044
SIC Code 2836

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.